Anti-Glomulin (GLMN) Polyclonal Antibody for WB, ELISA - Q92990

Core Product Specifications and Parameters

Biological Background: Glomulin Function and Localization

• Glomulin (GLMN) is a regulatory component of cullin-RING-based SCF E3 ubiquitin-protein ligase complexes. It inhibits E3 ligase activity by binding to RBX1 and disrupting its interaction with the E2 enzyme CDC34, thereby inhibiting RBX1-mediated neddylation of CUL1. Related references: PMID:22405651, PMID:22748924
• It is required for normal stability and cellular levels of key SCF complex components, including FBXW7, RBX1, CUL1, CUL2, CUL3, and CUL4A, contributing to the regulation of CCNE1 and MYC levels.
• Essential for normal development of the vasculature. Related references: PMID:11845407
• Contributes to the regulation of RPS6KB1 phosphorylation. Related references: PMID:11571281
• Ubiquitously expressed in human tissues.
• Post-translationally modified by acetylation and phosphorylation.
• Associated with disease variants and alternative splicing.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the C-terminal region (aa 405–594) of human Glomulin. This region may confer specificity for isoforms containing this sequence; consult sequence alignments for cross-reactivity predictions.
• For Western blotting, a band at approximately 68 kDa is expected. Optimize loading controls and antibody dilution using positive control lysates from human or mouse tissues/cells known to express GLMN.
• For ELISA, consider coating with the recombinant immunogen or native protein in the appropriate buffer system, and validate with known standards.
• Since the antibody is polyclonal, batch-to-batch consistency should be monitored; it is recommended to pre-adsorb or affinity-purify if needed for highly specific assays.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic developers and researchers with comprehensive access to IVD raw materials. This anti-Glomulin antibody fits ubiquitin ligase and cardiovascular research workflows, and we offer antibody pairs, bulk polyclonal antibodies, and ancillary reagents tailored to your assay development. Our sourcing network also covers rare targets, ensuring continuity from concept to clinic.